Symbiosis Boosts Business Development Team to Support US Growth

Stirling, UK-based contract manufacturing organization (CMO) Symbiosis Pharmaceutical Services has boosted its business development team to support its growth and continued development in the U.S.
 
Business development manager Helen Caddy-Leach will be responsible for maximizing the CMO’s presence in the U.S. market, working with new and existing clients to ensure the continued successful delivery of sterile biomanufacturing services to U.S. clients.

Symbiosis recently relocated to new premises on Massachusetts Avenue in the heart of the global biotech hub of Cambridge, MA, with Technology Square and Kendall Square only minutes from the new office.
 
Helen Caddy-Leach is Symbiosis' new business development manager.

The U.S. continues to be a significant growth area for the Scottish CMO, with more than 30% of annual revenues generated from this key geographical market. This strategic office move brings Symbiosis closer to its existing clients while representing a platform on which to further boost the company’s profile while positioning it for continued growth in North America.
 
Helen’s previous experience includes time as commercial manager for an analytical services company and prior to that with a specialist in life sciences decontamination services.
 
"Helen’s experience means she has a strong understanding of GMP and the sterile cleanroom environment which gives her an excellent grounding for her role here at Symbiosis," said Colin MacKay, chief executive officer, Symbiosis. "Helen will support the growth of the business in the U.S. Biopharma continues to significantly grow in this market, especially the number of small to mid-size and virtual companies, and Symbiosis is quickly becoming the foremost CMO for the outsourcing of small-scale sterile filling."
 
The appointment follows the recent announcement that Symbiosis and Freeline Therapeutics, a UK biotech focused on developing curative viral vector gene therapies for chronic systemic diseases, have been jointly awarded a collaborative grant of £1.3 million ($1.65m) from Innovate UK in partnership with the Cell and Gene Therapy Catapult (CGTC) in Stevenage, UK.
 
The Freeline-led project will see Symbiosis develop an innovative UK-based drug substance/drug product viral vector supply chain solution intended to increase the speed of the Freeline production cycle by over 25%.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com